Evidence map›Paper›PMID 30337617›Full record

ArticleScientific reports2018

Chronic kidney failure mineral bone disorder leads to a permanent loss of hematopoietic stem cells through dysfunction of the stem cell niche.

Marina A Aleksinskaya, Matthieu Monge, Michiel Siebelt, Edith M Slot, Karin M Koekkoek, Ruben G de Bruin, Ziad A Massy, Harrie Weinans, Ton J Rabelink, Willem E Fibbe and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Transcriptomics: a Solution for Renal Osteodystrophy?Current osteoporosis reports · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Marina A Aleksinskaya *Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Matthieu Monge *Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Michiel SiebeltOrthopaedic Research Laboratory, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6624-7223
Edith M SlotDepartment of Immunohematology and Blood transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Karin M KoekkoekDepartment of Internal Medicine (Nephrology) and the Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Ruben G de BruinDepartment of Internal Medicine (Nephrology) and the Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Ziad A MassyDivision of Nephrology, Ambroise Paré Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Boulogne-Billancourt/Paris, and INSERM U-1018, CESP Team 5 (EpReC, Renal & Cardiovascular Epidemiology), Villejuif, France.
Harrie WeinansDepartment of Orthopaedics, University Medical Center Utrecht, Utrecht, The Netherlands.
Ton J RabelinkDepartment of Internal Medicine (Nephrology) and the Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Willem E FibbeDepartment of Immunohematology and Blood transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Anton Jan van ZonneveldDepartment of Internal Medicine (Nephrology) and the Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands. a.j.vanzonneveld@lumc.nl.
Melissa van PelDepartment of Immunohematology and Blood transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Leiden University Medical Center · NLErasmus MC · NLInserm · FRUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In chronic kidney disease (CKD), endothelial injury, is associated with disease progression and an increased risk for cardiovascular complications. Circulating cells with vascular reparative functions are hematopoietic and also reduced in CKD. To explore the mechanistic basis behind these observations, we have investigated hematopoietic stem cell (HSC) homeostasis in a mouse model for non-progressive CKD-mineral and bone disorder with experimentally induced chronic renal failure (CRF). In mice subjected to 12 weeks of CRF, bone marrow HSC frequencies were decreased and transplantation of bone marrow cells from CRF donors showed a decrease in long-term HSC repopulation compared to controls. This loss was directly associated with a CRF-induced defect in the HSC niche affecting the cell cycle status of HSC and could not be restored by the PTH-reducing agent cinacalcet. In CRF, frequencies of quiescent (G0) HSC were decreased coinciding with an increase in hematopoietic progenitor cells (HPC) in the S-and G2-phases of cell cycle. Moreover, in CRF mice, HSC-niche supporting macrophages were decreased compared to controls concomitant to impaired B lymphopoiesis. Our data point to a permanent loss of HSC and may provide insight into the root cause of the loss of homeostatic potential in CKD.

Indexed as

Stem Cell NicheAnimalsBone DensityBone Marrow DiseasesCell CountCell CycleChronic Kidney Disease-Mineral and Bone DisorderCinacalcetDisease Models, AnimalEndothelium, VascularFemaleHematopoietic Stem CellsHomeostasisLymphopoiesisMacrophagesMiceCinacalcet

Identifiers

PMID30337617
PMCPMC6194087
OpenAlexW2897635568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.